Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio (Nasdaq: VOR) reported that on August 1, 2026, its Board Compensation Committee granted stock options for an aggregate 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees.

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) reported that on August 1, 2026, its Board Compensation Committee granted stock options for an aggregate 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees. The awards were approved as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and issued pursuant to the 2023 Inducement Plan.

The stock options have a ten-year term and an exercise price of $21.15 per share, equal to the closing price on the grant date. Options and RSUs each vest over four years, starting with 25% after 12 months and the remainder vesting monthly (options) or quarterly (RSUs), subject to continued employment.

Argus Aug 4 session 8 alerts

+3.92% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – VOR

+8.6% Peak Tracked

-2.5% Trough Tracked

$1.22B Market Cap

In the Aug 4 session, VOR gained 3.92%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Vor’s prior inducement-grant announcements recorded -2.38% and -6.25% 24-hour reactions. That histor...

Analysis

Vor’s prior inducement-grant announcements recorded -2.38% and -6.25% 24-hour reactions. That history frames today’s awards as a recurring equity-award signal; the active resale registration and moderate short positioning remain relevant risks to monitor.

Key Figures

Stock options: 32,550 shares Restricted stock units: 6,900 shares Newly hired employees: 5 employees +4 more

Stock options

32,550 shares

August 1, 2026 grant

Restricted stock units

6,900 shares

August 1, 2026 grant

Newly hired employees

5 employees

Recipients of the inducement awards

Exercise price

$21.15 per share

Equal to the closing price on the grant date

Option term

10 years

Term of the stock options

Option vesting

25% after 12 months; remaining shares monthly over 36 months

Subject to continued employment

RSU vesting

25% after 12 months; remaining shares quarterly over 36 months

Subject to continued employment

Historical Context

5 past events · Latest: Jul 07

5 events

1. Jul 07

   Board appointment

   24h Move

   +1.0%

   Added biopharma leadership experience while filling a board vacancy after a director’s departure.

2. Jul 02

   Inducement grant

   24h Move

   -2.4%

   Granted inducement options and RSUs to newly hired employees under the company plan.

3. Jun 08

   NMPA approval

   24h Move

   +1.0%

   China NMPA approved telitacicept for Sjögren’s disease, adding a fifth indication.

4. Jun 08

   NMPA approval

   24h Move

   +1.0%

   China NMPA conditionally approved telitacicept for IgA nephropathy, its fourth indication.

5. Jun 01

   Inducement grant

   24h Move

   -6.3%

   Granted equity awards to newly hired employees under the 2023 Inducement Plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"restricted stock units (“RSUs”) representing the right to receive"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"an exercise price of $21.15 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 32,550 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 6,900 shares of Vor Bio’s common stock to 5 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

The stock options have a ten-year term and an exercise price of $21.15 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

 

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Vor Bio (NASDAQ: VOR) grant on August 1, 2026?

Vor Bio granted stock options for an aggregate 32,550 shares on August 1, 2026. According to Vor Bio, the options have a ten-year term and an exercise price of $21.15 per share, matching the closing price on the grant date.

How many RSUs did Vor Bio (VOR) award as inducement grants in August 2026?

Vor Bio awarded RSUs representing 6,900 shares of common stock to five new employees. According to Vor Bio, these RSUs were granted as material inducements to employment under its 2023 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).

What are the vesting terms for Vor Bio’s August 2026 stock option grants (VOR)?

Vor Bio’s August 2026 options vest over four years, with 25% after 12 months and the rest monthly. According to Vor Bio, continued employment is required for vesting, and the options carry a ten-year term at $21.15 per share.

How do Vor Bio’s August 2026 RSU grants (NASDAQ: VOR) vest over time?

Vor Bio’s August 2026 RSUs vest over four years, with 25% vesting after 12 months and the remainder quarterly. According to Vor Bio, vesting is contingent on the employees’ continued employment and governed by the 2023 Inducement Plan and award agreements.

Why were the August 1, 2026 equity awards by Vor Bio (VOR) made under Nasdaq Listing Rule 5635(c)(4)?

Vor Bio designated these grants as material inducements to employment for five new hires. According to Vor Bio, this classification allows equity awards outside stockholder-approved plans, consistent with Nasdaq Listing Rule 5635(c)(4), using its 2023 Inducement Plan as the governing framework.

What is the exercise price of Vor Bio’s August 2026 inducement stock options (VOR)?

The exercise price is $21.15 per share for the August 2026 inducement options. According to Vor Bio, this price equals the closing price of its common stock on the option grant date, and the options remain exercisable for ten years, subject to their terms.